Drug Manufacturer

Activist investor Starboard Value takes $1 billion stake in Pfizer

Starboard has also approached Ian Read, a former Pfizer CEO, and Frank D'Amelio, who served as CFO until 2021, and both have expressed interest in helping the activist investor

Himachal govt to implement Bulk Drug Park Project on its own, says CM Sukhu

The Himachal Pradesh government will implement the Bulk Drug Park Project on its own and provide land and electricity at subsidised rates to the investors, Chief Minister Sukhvinder Singh Sukhu said on Wednesday. The project worth Rs 1,000 crore aims to set up a mega drug manufacturing facility spanning 570 hectares in the Haroli assembly segment of Una district. Intervening during Industries Minister Harshwardhan Chauhan's reply to a question by Congress's Kewal Singh Pathania on the Bulk Drug Park, Sukhu said the terms and conditions of the project would be revised after 10 years. Water and electricity would be supplied at commercial rates and charges would be levied for waste, solid waste, and steam management, he added. Sukhu also blamed the previous BJP government for allegedly failing to secure the interests of the state while signing memorandums of understanding for hydropower and other projects. Agreements for Dhaulasidh, Luhri and Sunni hydropower projects were signed aga

60 drug makers join govt scheme to modernise pharma manufacturing units

Indian pharmaceutical companies recently came under the scanner after global supplies of certain medicines were found to be toxic

USFDA highlights quality concerns over drugs manufactured in India

USFDA launches QMM program to reduce drug shortages and improve supply chain issues

Lupin, Eugia recall products from US over manufacturing issues: USFDA

Drugmaker Lupin and a unit of Aurobindo Pharma are recalling products from the American market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), a US-based unit of Lupin is recalling a medication used to treat bacterial infections. Baltimore-based Lupin Pharmaceuticals Inc is recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) due to "failed content uniformity specifications". The affected lot has been produced at the company's Mandideep-based manufacturing plant in Madhya Pradesh. The company commenced the Class II nationwide (US) recall on May 30 this year. The US health regulator stated that New Jersey-based Eugia US LLC, a subsidiary of Aurobindo Pharma, is recalling 70,125 vials of Dexamethasone Sodium Phosphate injection USP. The company is recalling the affected lot due to "failed impurities/degradation specifications", USFDA said. Eugia com

Zero-tolerance against those who compromise quality of medicines: Mandaviya

The Indian pharma industry should strive to maintain the reputation of India as the 'Pharmacy of the World' which was established during the Covid-19 crisis, Union Minister for Chemicals & Fertilizers and Health & Family Welfare, Mansukh Mandaviya said on Friday at the closing ceremony of IPA's 8th Global Pharmaceutical Quality Summit.Day two of the summit witnessed industry leaders shedding light on industry advancements, continuous manufacturing, regulatory expectation, digital technologies in pharmaceutical manufacturing and learnings from other industries."The country could achieve this feat with the shared responsibility of the Government and pharma industry during the global crisis. The industry relentlessly worked to follow all instructions given by the Government, knowing the huge responsibility on them and made all the medicines required for treatment of Covid-19 available. They also supported the Government to produce the various vaccines", Mandviya said.The ...

India-made stimulants, Covid drugs dominate illegal imports in Switzerland

Around 150 of the packages seized were connected with the Coronavirus including anti-parasitics containing ivermectin, medicinal products containing hydroxychloroquine or antibiotics from India

Govt okays ramping up production of remdesivir; firms commit to cut price

The current total installed capacity of the seven manufacturers of remdesivir is around four million vials per month

HCQ's emergency use revocation by US may not hit India's exports

This is because while emergency-use authorisation for treating Covid-19 was a recent move, the drug has been used since years for rheumatoid arthritis and lupus

More stringent rules on drug safety

The Central Drugs Standard Controls Organization is putting the details of all its processes online